Compare ADX & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADX | CLDX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1996 | 1995 |
| Metric | ADX | CLDX |
|---|---|---|
| Price | $25.96 | $37.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | 299.4K | ★ 926.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | N/A | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $20.91 | $19.72 |
| 52 Week High | $26.49 | $40.30 |
| Indicator | ADX | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 61.74 |
| Support Level | $24.45 | $28.51 |
| Resistance Level | $26.49 | $40.30 |
| Average True Range (ATR) | 0.33 | 1.65 |
| MACD | -0.08 | 0.07 |
| Stochastic Oscillator | 72.45 | 91.92 |
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector-neutral approach. The fund has a diversified equity portfolio that consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.